



WBB Securities Retained as Financial Advisor to Navidea Biopharmaceuticals, Inc.

Navidea closes \$25 million debt financing with GE Capital to finance and manage commercialization of approved radiopharmaceutical

**For Immediate Release
June 26, 2013**

SAN DIEGO, CA – WBB Securities acted as sole financial advisor to a transaction for Navidea Biopharmaceuticals, Inc. in the placement of \$25 million in debt financing from GE Capital. Navidea intends to utilize the credit line for the commercialization of Lymphoseek, its commercial radiopharmaceutical product for use in intra operative lymph node mapping.

Each year, the StarMine Analyst Awards recognize analysts who have shown exemplary performance either as stock pickers or as earnings estimators during the prior year. The 2013 stock picking awards for the United States are based on the 2012 calendar-year performance of recommendations. Only analyst performance on companies that are based in the United States are included in the awards calculations.

WBB Securities is often quoted in news media and has contributed opinion articles on a wide range of healthcare and economic issues. Steve Brozak is a guest contributor to Forbes.com, ABCNews.com and Bloomberg.com, frequently publishing opinion articles in those publications.

About WBB Securities

WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients. The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. www.wbbsec.com

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including NAV4694, NAV5001, Manocept™ and NAV1800 (RIGScan™), to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) Injection, Navidea's first commercial product from the Manocept platform, was approved by the

FDA in March 2013. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.